BriaCell Announces Clinical Supply Agreement with BeiGene for Bria-OTS™ First in Human Study
May 28 2024 - 8:00AM
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX:
BCT) (“BriaCell” or the “Company”), a clinical-stage
biotechnology company that develops novel immunotherapies to
transform cancer care, announces a clinical supply agreement with
BeiGene, Ltd. (NASDAQ: BGNE) (“BeiGene”) to evaluate the safety and
efficacy of Bria-OTS™, BriaCell’s next generation immunotherapy, in
combination with BeiGene's anti-PD-1 antibody, tislelizumab, for
the treatment of advanced heavily pretreated metastatic breast
cancer.
“We are extremely excited about partnering with
BeiGene on this novel immunotherapy approach with planned expansion
to prostate and other cancers,” stated Dr. William V. Williams,
BriaCell’s President & CEO. “This agreement marks another
positive milestone for BriaCell in our commitment to transform
cancer care.”
“The Bria-OTS™ platform capitalizes on our
success with Bria-IMT™, which has shown clinical benefit after
check point inhibitors (CPIs) resistance,” stated Dr. Del Priore,
BriaCell’s Chief Medical Officer. “In our randomized Phase 2 and
other trials of Bria-IMT™, BriaCell immunotherapy has shown
survival and clinical benefit in patients with central nervous
system (CNS) metastases and after progression on antibody drug
conjugates (ADCs). The Bria-OTS™ platform is the next generation
off-the-shelf therapy with enhanced potency. There is rationale to
predict that combining Bria-OTS™ with tislelizumab may impart
additional benefit in this refractory patient population.”
The limited access Phase 1/2 clinical trial will
initially evaluate the safety and efficacy of Bria-OTS™ alone in
breast cancer and later in combination with tislelizumab. BriaCell
also plans to evaluate Bria-OTS™ in prostate and other cancers.
About BriaCell Therapeutics
Corp.
BriaCell is a clinical-stage biotechnology
company that develops novel immunotherapies to transform cancer
care. More information is available at https://briacell.com/.
Safe Harbor
This press release contains “forward-looking
statements” that are subject to substantial risks and
uncertainties. All statements, other than statements of historical
fact, contained in this press release are forward-looking
statements. Forward-looking statements contained in this press
release may be identified by the use of words such as “anticipate,”
“believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,”
“seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,”
“target,” “aim,” “should,” “will,” “would,” or the negative of
these words or other similar expressions, although not all
forward-looking statements contain these words. Forward-looking
statements, including those about combining Bria-OTS™ with
tislelizumab resulting in additional benefits in the refractory
patient population; BriaCell's Phase 1/2 clinical trial in advanced
breast cancer initially evaluating the safety and efficacy of
Bria-OTS™ alone and later in combination with tislelizumab; and
BriaCell evaluating Bria-OTS™ in prostate and other cancers, are
based on assumptions as to future events that may not prove to be
accurate. These and other risks and uncertainties are described
more fully under the heading “Risks and Uncertainties” in the
Company's most recent Management’s Discussion and Analysis, under
the heading "Risk Factors" in the Company's most recent Annual
Information Form, and under “Risks and Uncertainties” in the
Company's other filings with the Canadian securities regulatory
authorities and the U.S. Securities and Exchange Commission, all of
which are available under the Company's profiles on SEDAR+ at
www.sedarplus.ca and on EDGAR at
www.sec.gov. Forward-looking statements contained
in this announcement are made as of this date, and BriaCell
Therapeutics Corp. undertakes no duty to update such information
except as required under applicable law.
Neither the Toronto Stock Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the Toronto Stock Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Contact Information
Company Contact:William V.
Williams, MDPresident &
CEO1-888-485-6340info@briacell.com
Media Relations:Jules AbrahamCORE
IRjulesa@coreir.com
Investor Relations Contact:CORE
IRinvestors@briacell.com
BriaCell Therapeutics (NASDAQ:BCTXW)
Historical Stock Chart
From Jul 2024 to Aug 2024
BriaCell Therapeutics (NASDAQ:BCTXW)
Historical Stock Chart
From Aug 2023 to Aug 2024